论文部分内容阅读
目的:探讨术前艾迪注射液联合新辅助化疗用于治疗非小细胞肺癌(NSCLC)的疗效。方法:选取NSCLC患者55例,根据在新辅助化疗时是否联合使用艾迪注射液分为对照组与治疗组,对照组未使用艾迪注射液,共20例,治疗组使用艾迪注射液,共35例。观察两组患者近期疗效、手术时间、出血量、切除率以及毒副反应,并通过流式细胞术检测治疗前后患者外周血CD4+CD25+调节性T细胞数量。结果:与对照组相比,治疗组患者手术出血量显著下降(P<0.05),分别为(615.49±114.08)mL与(530.15±104.55)mL;治疗总有效率显著上升(P<0.05),分别为30.00%,45.71%;白细胞减少发生率显著下降(P<0.05),分别为60.00%,37.14%;与治疗前相比,所有患者外周血CD4+CD25+调节性T细胞显著降低(P<0.05),以治疗组患者降低更加明显(P<0.05)。结论:艾迪注射液联合新辅助化疗可提高NSCLC的治疗效果,提高肿瘤免疫,减少不良反应。
Objective: To investigate the efficacy of preoperative Aidi injection combined with neoadjuvant chemotherapy in the treatment of non-small cell lung cancer (NSCLC). Methods: Fifty-five patients with NSCLC were divided into control group and treatment group according to whether or not Aidi Injection was used in neoadjuvant chemotherapy. Aidi Injection was not used in control group, 20 cases in total. Aidi Injection, A total of 35 cases. The curative effect, operation time, blood loss, resection rate and toxicity of the two groups were observed. The number of CD4 + CD25 + regulatory T cells in peripheral blood of patients before and after treatment was detected by flow cytometry. Results: Compared with the control group, the bleeding volume in the treatment group was significantly decreased (P <0.05), and the total effective rate was (615.49 ± 114.08) mL and (530.15 ± 104.55) mL, respectively (30.00%, 45.71% respectively). The incidence of leukopenia decreased significantly (P <0.05), which was 60.00% and 37.14%, respectively. Compared with those before treatment, CD4 + CD25 + regulatory T cells were significantly decreased in all patients (P < 0.05), the treatment group patients decreased more significantly (P <0.05). Conclusion: Aidi injection combined with neoadjuvant chemotherapy can improve the therapeutic effect of NSCLC, improve tumor immunity and reduce adverse reactions.